Novo Nordisk, the maker of weight loss drug Wegovy, will lay off about 9,000 people as it grapples with rising competition in ...

On September 10, Novo Nordisk shared in a press release that it intends to eliminate 9,000 positions from its global ...

The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative ...

Novo Nordisk A/S (NYSE:NVO) on Sunday presented data from the STEER real-world study of evidence gathered from actual patient ...

Novo Nordisk, the maker of blockbuster weight loss medication Wegovy, will cut 9,000 jobs amid growing competition in the ...

Investors favor Eli Lilly (LLY), but I argue that Novo (NVO) stock outperforms LLY in almost every aspect while trading at a ...

A class-action lawsuit accuses CVS Caremark of denying medically necessary treatments by stopping coverage of Zepbound, Eli ...

Eli Lilly dominates obesity and diabetes treatments with soaring tirzepatide sales and promising oral drug data. Find out why ...

The Danish pharma giant outlined proposals to shed around 11% of its 78,400-strong workforce amid stiff competition from ...

The Danish pharmaceutical giant, which is looking to revive growth, used to be Europe's most valuable company listed on ...

Ozempic and Wegovy maker Novo Nordisk is axing 9,000 jobs in a bid to fend off rivals and streamline its operations.

The restructuring, which would eliminate 11% of the company's workforce, aimed to reduce organizational complexity and speed ...